Navigation Links
Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study

Phase III trial planned
Abstracts: 2000, 2002

CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of a Phase I/IIa study presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago demonstrate the clinical activity of cilengitide in patients with newly diagnosed glioblastoma – a particularly aggressive form of brain tumor. Cilengitide is a highly selective integrin inhibitor targeting the tumor and its vasculature.

Fifty-two patients with newly diagnosed glioblastoma were treated with cilengitide, combined with a standard regimen of radiotherapy and temozolomide following tumor resection or biopsy. The study reached the predefined primary endpoint with 69% of patients being alive and progression free at six months, and showed a median progression free survival (PFS) of 8.1 months. In a defined patient subgroup with the methylated MGMT gene promoter in the tumor tissue, 91% of patients had six months PFS and the median has not yet been reached. These results are encouraging when compared to the historical control of the EORTC-NCIC phase III trial [overall population: 54% 6 months PFS, median PFS of 6.9 months;(1) methylated MGMT gene promoter subgroup: 69% PFS and 10.3 months median PFS].(2)

Lead investigator Dr. Roger Stupp of the University of Lausanne Hospital in Switzerland, commented: “We are excited by these findings. They demonstrate the potential of cilengitide to make a real difference to the outcome of patients with this aggressive type of brain cancer, where currently available treatment options are limited and prognosis is poor. We look forward to learning more about the benefits of this promising agent in larger patient populations.”

Also presented at ASCO was a Phase IIa randomized multicenter trial, examining two dosing levels of cilengitide monotherapy (500mg and 2000mg) in 81 patients with recurrent gliobl
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
11. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
Post Your Comments:
(Date:3/30/2015)... 2015  Caris Life Sciences® today announced the presentation ... may have potentially significant benefit in a select subset ... highlighted today in an oral presentation in a Plenary ... Annual Meeting on Women,s Cancer in Chicago, ... of four presented at the annual meeting that utilizes ...
(Date:3/30/2015)... 30, 2015  MedAptus® today announced the launch ... simplify pre-care needs for busy inpatient provider teams. ... assign patients to hospitalists or other rounding providers ... other requirements such as ensuring patient safety, proper ... In an increasingly ...
(Date:3/30/2015)... , March 30, 2015  Cochlear Corporation Vice ... to leave Cochlear to join Valencia Technologies ( ... Jeff Greiner , who is the CEO ... Market Development and will be responsible for generating ... Valencia,s coin-sized neuromodulation device in ...
Breaking Medicine Technology:Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 2Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 3Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 4MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 2MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 3Cochlear VP of U.S. Sales Jerry Schloffman Accepts Chief of Market Development Position at Valencia Technologies 2
... U.S. Dept. of Defense Continues Study of Copper ... Infections and Improving Indoor Air Quality, NEW ... clinical trails determining the,antimicrobial effectiveness of copper, brass ... Association, announced CDA President Andrew G.,Kireta Sr. ...
... Serious Adverse Reactions, BERKELEY HEIGHTS, N.J., Nov. ... findings from the initial clinical,dosing of G4544, the ... treatment for diseases associated with accelerated bone loss. ... volunteers, has shown good,tolerance with oral bioavailability of ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:3/30/2015)... The fertility team at Ada IVF ... questions to give intended parents across the globe a ... , After unveiling the most affordable, non-sharing ... clinic has witnessed an increase in fertility patients. Led ... attentive reproductive care — with all-inclusive IVF treatment options ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 “ iCareTech ” ... Report, which takes a look at the latest and coolest ... NewsWatch special reporter and technology expert, conducted the review and ... band that’s dedicated to the medical and health fields. , ... of conversation over the past couple of years. Well, at ...
(Date:3/30/2015)... 2015 Healthy, radiant skin can be ... staff of pharmacists is specially trained and skilled in ... eczema and other conditions. , Most people are unaware ... and/or PCP to tackle most skin conditions and offer ... employed specialty-trained pharmacists who have experience in consulting with ...
(Date:3/30/2015)... A key protein previously implicated in ... important role in the response to viral infection, according ... School of Medicine at Mount Sinai published today in ... associated with inflammation, part of the body’s response to ... in to attack invaders like bacteria and viruses, and ...
(Date:3/30/2015)... In a recent report published by ... is championing effective drug and alcohol treatment for victims ... recover funds to stabilize the addiction treatment programs, and ... drug and alcohol addiction. Harbor Village Detox is extending ... use disorders in New Jersey, in hopes to help ...
Breaking Medicine News(10 mins):Health News:Top Fertility Clinic in Cyprus Answers Key Questions on Egg Donation Process 2Health News:Top Fertility Clinic in Cyprus Answers Key Questions on Egg Donation Process 3Health News:Top Fertility Clinic in Cyprus Answers Key Questions on Egg Donation Process 4Health News:World’s First Medical Intelligent Band was Featured on NewsWatch Television on January 30, 2015 2Health News:MedX Pharmacy Offers Skin Care Tips 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 3Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3
... in Desso ... Turf, BRUSSELS, Belgium, ... in a few synthetic turf,fields. The fields in question are not manufactured by ... assured that,their pitch doesn,t contain any lead., All Desso synthetic turf products ...
... Eating out is common while traveling, but it,s important to ... Memorial Day marks the start of the summer holiday season, ... take a vacation from your diet, cautions Elizabeth Schaub, a ... , Dining out is common when people are on holidays, ...
... tool for mopping up the clumps of mutant protein ... engineered a virus to make an intracellular antibody or ... the brain cells of people with Huntington,s. , Injecting ... mutant huntingtin improves their ability to move their limbs, ...
... in 2007but the price of phosphate fertilizers then doubled ... months from February through April 2008. The effects on ... in Sichuan Province, Chinaa major production area for nitrogen ... had already imposed dramatic new export duties on fertilizer, ...
... and a mathematician may seem like an unlikely duo, but ... and kept millions of sailors from getting lost at sea. ... Rockefeller University, is making history of their own. By using ... have become the first to see, in real time and ...
... sun-related vision damage without proper protection , , SUNDAY, May ... you,re thinking about ultraviolet (UV) protection as the weather ... the sun,s UV rays has been linked to a ... photokeratitis and corneal degenerative changes, according to the American ...
Cached Medicine News:Health News:It's Safe to Play on Desso Synthetic Turf 2Health News:It's Safe to Play on Desso Synthetic Turf 3Health News:Don't Leave Diet Out to Lunch on Vacation 2Health News:'Intrabody' can mop up mutant protein in Huntington's disease model 2Health News:World fertilizer prices continue to soar, scientists stress need for fertilizer efficiency 2Health News:World fertilizer prices continue to soar, scientists stress need for fertilizer efficiency 3Health News:Scientists image a single HIV particle being born 2Health News:Scientists image a single HIV particle being born 3Health News:Just Like Skin, Eyes Can 'Burn' in Strong Sun 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: